Valuation IDEXX Laboratories, Inc.
Stocks
IDXX
US45168D1046
Medical Equipment, Supplies & Distribution
|
Market Closed -
Nasdaq
00:00:00 28/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 561.25 USD | -1.57% |
|
+0.60% | -17.04% |
| 10-27 | UBS Adjusts IDEXX Laboratories Price Target to $627 From $670, Maintains Neutral Rating | MT |
| 10-20 | Jefferies Adjusts Price Target on IDEXX Laboratories to $705 From $795 | MT |
Company Valuation: IDEXX Laboratories, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55,833 | 33,786 | 46,098 | 33,854 | 54,022 | 44,216 | - | - |
| Change | - | -39.49% | 36.44% | -26.56% | 59.57% | -18.15% | - | - |
| Enterprise Value (EV) 1 | 56,612 | 35,022 | 46,592 | 34,434 | 54,690 | 44,583 | 44,117 | 43,316 |
| Change | - | -38.14% | 33.04% | -26.09% | 58.83% | -18.48% | -1.05% | -1.82% |
| P/E | 76.6x | 50.8x | 55.2x | 38.7x | 51.7x | 38x | 33.7x | 29.8x |
| PBR | 82.6x | 55.6x | 31x | 21.6x | 34.1x | 22.3x | 16.5x | 12.1x |
| PEG | - | -7.66x | 2.2x | 6.38x | 2.3x | 3x | 2.6x | 2.3x |
| Capitalization / Revenue | 17.4x | 10x | 12.6x | 8.69x | 12.6x | 9.36x | 8.6x | 7.88x |
| EV / Revenue | 17.6x | 10.4x | 12.7x | 8.83x | 12.7x | 9.44x | 8.58x | 7.72x |
| EV / EBITDA | 54.6x | 34.7x | 38.4x | 28.1x | 36.3x | 26.4x | 23.8x | 21.1x |
| EV / EBIT | 60.7x | 39x | 42.5x | 30.5x | 40.2x | 29.2x | 26.1x | 22.9x |
| EV / FCF | 89x | 88.9x | 60.3x | 42.6x | 51.7x | 38x | 33.7x | 29.6x |
| FCF Yield | 1.12% | 1.13% | 1.66% | 2.35% | 1.93% | 2.63% | 2.97% | 3.38% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 8.6 | 8.03 | 10.06 | 10.67 | 13.08 | 14.76 | 16.66 | 18.84 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 3,215 | 3,367 | 3,661 | 3,898 | 4,304 | 4,724 | 5,143 | 5,610 |
| EBITDA 1 | 1,037 | 1,011 | 1,212 | 1,225 | 1,505 | 1,689 | 1,854 | 2,056 |
| EBIT 1 | 932 | 898.8 | 1,097 | 1,128 | 1,360 | 1,528 | 1,692 | 1,888 |
| Net income 1 | 744.8 | 679.1 | 845 | 887.9 | 1,059 | 1,179 | 1,311 | 1,464 |
| Net Debt 1 | 779.2 | 1,236 | 493.9 | 579.3 | 667.8 | 367.6 | -98.49 | -899.7 |
| Reference price 2 | 658.46 | 407.96 | 555.05 | 413.44 | 676.53 | 561.25 | 561.25 | 561.25 |
| Nbr of stocks (in thousands) | 84,794 | 82,817 | 83,052 | 81,885 | 79,851 | 78,781 | - | - |
| Announcement Date | 02/02/22 | 06/02/23 | 05/02/24 | 03/02/25 | 02/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 38.62x | 9.59x | 26.82x | -.--% | 44.92B | ||
| 34.7x | 4.1x | 15.76x | 2.47% | 181B | ||
| 23.76x | 4.66x | 16.26x | 1.17% | 117B | ||
| 20.26x | 3.52x | 12.6x | 2.99% | 116B | ||
| 30.71x | 2.97x | 11.98x | 2.32% | 89.94B | ||
| 18.1x | 0.21x | 13.1x | 0.72% | 62.97B | ||
| 31.43x | 7.87x | 20.24x | 1.26% | 55.43B | ||
| 38.95x | 3.6x | 12.25x | 2.13% | 53.49B | ||
| 40.64x | 3.29x | 12.25x | 0.53% | 33.87B | ||
| 45.62x | 1.26x | 11.74x | 0.22% | 29.56B | ||
| Average | 32.28x | 4.11x | 15.30x | 1.38% | 78.51B | |
| Weighted average by Cap. | 30.09x | 4.06x | 15.13x | 1.78% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- IDXX Stock
- Valuation IDEXX Laboratories, Inc.
Select your edition
All financial news and data tailored to specific country editions
















